SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will
present new data from the open-label extension (OLE) of the Phase 2
OASIS trial for its investigative drug candidate etrasimod, a
next-generation, once-daily, oral, selective sphingosine
1-phosphate (S1P) receptor modulator, at the 15th Annual
Congress of the European Crohn's and Colitis Organisation
(ECCO). The congress is taking place February 12-15, 2020, in Vienna, Austria.
Arena is presenting additional data on etrasimod and the unmet
need in IBD, as well as hosting a dinner symposium with focused
discussion on the integration of histology into a treat-to-target
strategy.
Etrasimod Presentation Details:
Title: Faecal
calprotectin and C-reactive protein levels are associated with long
term clinical and endoscopic outcomes: Analysis of the OASIS OLE
trial of etrasimod for UC
Abstract Number:
EC20-1131
Poster Number: P682
Date/Time: February 14,
12:30 - 13:30 CET
Title: Pharmacokinetics
and circulating total lymphocyte count pharmacodynamic response
from single and multiple oral doses of etrasimod in Japanese and
Caucasian healthy male subjects
Abstract Number:
EC20-0558
Poster Number: P396
Date/Time: February 14, 12:30
- 13:30 CET
Title: Patient-reported
disease activity in a large sample of ulcerative colitis patients
using social media-delivered questionnaires
Abstract
Number: EC20-1149
Poster Number: P157
Date/Time: February 14,
12:30 - 13:30 CET
Symposium Details:
Dinner Symposium Title:
HYPE, HOPE or REALITY? Integrating histology into a
treat-to-target strategy in UC
Speakers: Chair: Prof.
William J. Sandborn, MD, Prof. Geert
D'Haens, MD, & Prof. Peter
Lakatos, PhD
Date/Time: February 14,
18:40–19:40 CET
Location: Messe Wien, Parallel Hall C
About Arena of Care
The Arena of Care Award™ in
IBD is a competitive global grant designed to fund novel
patient-centric solutions. The Company will begin accepting
applications in March of 2020 for projects that seek to address the
myriad of psycho-social challenges that IBD patients and their
caregivers face, including but not limited to the improvement of
support for family members of patients, assisting patients in
taking greater ownership of their healthcare, and supporting the
education of patients on important disease-related topics. To
receive updates on Arena of Care, please visit
https://ibdaward.com/.
Find out more about Arena's ongoing clinical trials and its
competitive global grant, the Arena of Care Award in IBD, at booth
#43.
About Etrasimod
Etrasimod (APD334) is a next
generation, once-daily, oral, highly selective sphingosine
1-phosphate (S1P) receptor modulator, discovered by Arena, and
designed for optimized pharmacology and engagement of S1P receptor
1, 4 and 5 which may lead to an improved efficacy and safety
profile.
Etrasimod provides systemic and local effects on specific immune
cell types and has the potential to treat multiple immune-mediated
inflammatory diseases including ulcerative colitis, Crohn's
disease, eosinophilic esophagitis, atopic dermatitis, and alopecia
areata.
Etrasimod is an investigational compound that is not approved
for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
uniquely positioned to develop best-in-disease medicines with
optimized efficacy and safety for patients globally. Our drive to
deliver a robust pipeline of novel, transformational medicines is
grounded in two decades of world class G-protein-coupled receptor
(GPCR) discovery research.
It is the breadth and depth of our portfolio, prioritization of
drug development to meet unmet patient needs, strong financial
health and growing, bold-thinking world-class team that gives Arena
the ingredients and passion to build a sustainable, vibrant next
generation pharmaceutical company.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "designed to", "will",
"seek to", "may", "potential", "uniquely positioned to," "drive
to," or words of similar meaning, or by the fact that they do not
relate strictly to historical or current facts. Such
forward-looking statements include statements about Arena's
presence at and participation in the ECCO Congress, data from
Arena's OASIS OLE study, the Arena of Care Award, and Arena's
drive, assets, programs, licenses, and partnerships. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include, without limitation, the following: results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results; the
timing and outcome of research, development and regulatory review
is uncertain; clinical trials and other studies may not proceed at
the time or in the manner expected or at all; enrolling subjects in
Arena's ongoing and intended clinical trials is competitive and
challenging; nonclinical and clinical data are voluminous and
detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; Arena expects to need additional funds to advance
all of its programs, and you and others may not agree with the
manner in which Arena allocates its resources; Arena's drug
candidates may not advance in development or be approved for
marketing; risks related to unexpected or unfavorable new data;
risks related to relying on partners and other third parties; risks
related to developing and commercializing drugs; Arena's and third
parties' intellectual property rights; and satisfactory resolution
of litigation or other disagreements with others. Additional
factors that could cause actual results to differ materially from
those stated or implied by Arena's forward-looking statements are
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Arena Media Contact:
IR@arenapharm.com
858-453-7200
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presence-at-the-european-crohns-and-colitis-organisation-ecco-congress-further-highlights-commitment-to-the-gi-community-301003183.html
SOURCE Arena Pharmaceuticals, Inc.